• About
  • Board
  • Expert Index
  • Podcasts
  • News
  • Sign up
  • Contact

Visit

VJHemOnc - Hematological Oncology
  • Home
  • Diseases
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myeloproliferative Neoplasms
    Myelodysplastic Syndromes
    Others
    View all Diseases
  • Trials
    • MUK Nine b
    • TEAMM
    • MUK Seven
    • PERSPECTIVE
    • Hokusai VTE-Cancer Study
    • ZUMA-3
    • UKALL14
    • MEDI4736
    • BMS-936558
    • BRIGHT AML1019
    • View all trials
  • Medicines
    • Levofloxacin
    • Edoxaban
    • AMG 330
    • Glasdegib
    • IMGN779
    • Avapritinib
    • Cirmtuzumab
    • Pegfilgrastim
    • Procarbazine
    • Filanesib
    • View all medicines
  • Topics
    • Disease Biology
    • Pharmacy
    • Surgery
    • Treatment
    • Communication
    • Perspectives
    • Policy
    • Psycho-Oncology
    • Supportive Care
    • Transplantation
    • View all topics
  • Conferences
    • HOPA 2018
    • EBMT 2018
    • iwAL 2018
    • UKONS 2017
    • ASH 2017
    • MPN Advances Day 2017
    • NCRI 2017
    • ESH 2017
    • Myeloma 2017
    • BOPA 2017
    • View upcoming conferences
    • View previous conferences
  • Features
    • About
    • Board
    • Expert Index
    • Podcasts
    • News
    • Sign up
    • Contact
0:49
Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
1:08
Can concepts from CLL be applied to other liquid and solid tumors?
Paolo Ghia
1:00
Why is personalized medicine important for CLL?
Petra Langerbeins
1:08
The impact of genetic testing on treatment selection in CLL
Anna Schuh
1:38
What are the economics of treating CLL?
John Gribben
1:14
Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins
2:08
How does an understanding of the microenvironment aid research in CLL?
Paolo Ghia
1:02
How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins
1:15
The role of transplant in CLL and Richter’s transformation today
Stephan Stilgenbauer
1:58
Whole genome sequencing in CLL: challenges and benefits
Anna Schuh
2:32
The importance of collaboration across fields and institutions
Dan Landau
2:23
Key considerations for mutation detection in CLL
Anna Schuh
2:10
Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins
2:02
Current research at Weill Cornell and the New York Genome Center
Dan Landau
1:07
Where are we with precision medicine for CLL?
John Gribben
2:09
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Please enter your details if you would like to receive the latest Hemonc news and updates

Continue
Video channels
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Multiple Myeloma
  • B-Cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Chronic Myeloid Leukemia
  • Amyloidosis
  • Hodgkin Lymphoma
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Terms of Use
  • Terms of Use
  • Privacy Policy